Qbtech
Qbtech develops FDA-cleared, NICE-recommended objective ADHD diagnostic technology (QbTest, QbCheck, QbMobile) used by 35,000+ clinicians across 18 countries to measure hyperactivity, impulsivity, and inattention.
- Company typePrivate
- Founded2002
- HeadquartersStockholm, Sweden
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Qbtech does
Qbtech AB is a Swedish medical-technology company founded in 2000 (incorporated 2002) by the Gillberg family and psychologist Fredrik Ulberstad, headquartered in Stockholm with wholly-owned subsidiaries in the United States, the United Kingdom, and Germany. The company develops FDA-cleared, NICE-recommended objective diagnostic and treatment-monitoring technology for ADHD, anchored on two core products: QbTest, an in-clinic hardware-based test using a headband and motion-tracking camera, and QbCheck, a web-based test deliverable in-clinic or remotely. Both measure the three core ADHD symptoms — hyperactivity, impulsivity, and inattention — and compare results to age- and sex-at-birth-matched normative data drawn from over one million test takers globally.
The product portfolio is completed by QbClinic (clinician administration portal), QbPath (patient-facing portal), QbMobile (smartphone-based assessment launched 2025), QbAdmin, and QbAcademy (digital training). Qbtech monetizes through two primary streams: per-test credits on the Growth plan starting at £65 / $68 / €75 per test, and tailored multi-year enterprise subscriptions with dedicated Customer Success Managers, API integrations, and per-patient or per-test billing. Distribution is direct via enterprise field sales and inside sales, supported by a team of clinical advisors.
Qbtech serves five primary verticals — virtual care providers, primary care, specialist care, private healthcare, and education — across 18 countries, with the NHS Focus ADHD national programme in England (70% of child clinics) and named customers including ADHD360, Legion Health, and Meridian Advanced Psychiatry. The company has secured four FDA 510(k) clearances, MDR certification, CE marking, and ISO 13485 and ISO 27001 certifications. Verdane invested as a growth-equity partner in 2022. Qbtech reports over 35,000 clinicians using its technology globally.
Qbtech firmographics
Firmographics- Name
- Qbtech
- Legal name
- Qbtech AB
- Website
- https://qbtech.com
- Company type
- Private
- Founded year
- 2002
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Qbtech develops FDA-cleared, NICE-recommended objective ADHD diagnostic technology (QbTest, QbCheck, QbMobile) used by 35,000+ clinicians across 18 countries to measure hyperactivity, impulsivity, and inattention.
- Ownership category
- akta.pro rank
Qbtech industry classification
Industry- Product category
- ADHD Diagnostics Software
- NAICS
- Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215), In-Vitro Diagnostic Substance Manufacturing (325413)
- SIC
- Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835), Services-Prepackaged Software (7372)
- akta.pro primary industry
- Home Diagnostic & Self-Test OTC Kits (HLAIADAO)
- akta.pro secondary industry
- Toxicology & Therapeutic Drug Monitoring Laboratories (HLAFAMAF)
Keywords
Where Qbtech is headquartered
LocationHeadquarters
- HQ city
- Stockholm
- HQ country
- Sweden
- HQ region
- Europe
Offices4 records
Markets served
Qbtech business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Operations
Revenue model
- QbCheck Software Subscription (Growth Plan): Per-test credits model with invoicing upfront. Test credits valid for 12 months from purchase date. Automatic renewal when test credits are used. Starting from £65 / $68 / €75 per test for the Growth tier.
- QbCheck Enterprise Plans: Tailored plans for at-scale providers with features including QbClinic test administrator, dedicated Customer Success Manager, expert training, self-guided learning modules, API integrations, and per patient or per test billing options.
- QbTest Hardware and Subscription: In-clinic testing solution with hardware components (headband, motion-tracking camera, and stand) combined with subscription for unlimited clinical user accounts and instantly generated reports. Includes secure end-to-end encryption.
- Professional Services and Training: Comprehensive onboarding, onsite training, on-request weekday support, and interactive training sessions with clinical experts included as part of product deployment.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Growth Plan - For clinics seeking assured growth |
| Subscription | Multi-year contract | Enterprise Plan - Tailored plan for at-scale providers |
| Subscription | Annual | QbTest - In-clinic hardware-based testing |
Go-to-market motion3 records
Distribution channels4 records
Marketing channels11 records
Qbtech product offering
Product offeringCore offering
Qbtech provides FDA-cleared, MDR-certified objective ADHD testing technology for healthcare providers. Its core offerings include QbTest, an in-clinic hardware-based assessment, and QbCheck, a web-based test usable remotely or in-clinic. Both products measure the three core ADHD symptoms (hyperactivity, impulsivity, inattention) using computerized attention-based tasks combined with motion tracking, comparing results to age- and sex-matched normative control groups.
Product overview
Qbtech offers a portfolio of clinically validated ADHD diagnostic and monitoring solutions centered on two FDA-cleared objective tests: QbTest (in-clinic hardware-based assessment) and QbCheck (flexible web-based platform usable in-clinic or remotely). These core products are supported by complementary platforms including QbClinic (clinician admin portal), QbPath (patient-facing portal for test completion), and QbAcademy (digital training). The portfolio measures the three core ADHD symptoms—hyperactivity, impulsivity, and inattention—through computerized tasks combined with motion tracking, comparing results to age and sex-matched normative data. All products are designed for use by clinicians in primary care, specialist care, virtual care, private practice, and educational settings.
Differentiator
Problem solved
Functional benefit
Brands
- QbCheck: Flexible at-home and in-clinic FDA-cleared ADHD test for children and adults (ages 6-60). Web-based objective ADHD testing platform with remote and in-clinic testing capabilities.
- QbTest
- QbClinic
- QbPath
Products and services
- QbTest FDA-cleared in-clinic ADHD assessment tool for individuals aged 6-60 that objectively measures hyperactivity, impulsivity, and inattention using hardware (headband and motion-tracking camera) combined with software. The 20-minute computer-based test tracks motor activity with 1mm precision and compares results to age and sex-matched normative data.
- QbCheck FDA-cleared, MDR-certified, CE-marked web-based ADHD test equivalent to QbTest but with increased flexibility and no hardware dependency. Can be administered in-clinic or remotely via the QbPath patient portal, with results compared to normative control groups. Includes integrated rating scales and supports treatment monitoring.
- QbClinic Clinician administration portal for QbCheck that enables management of patient profiles, multi-site clinics, test progress, reports, and access to support resources. Allows clinicians to assign objective tests and subjective assessments as a single task.
- QbPath Patient-facing portal for completing QbCheck assessments. Provides step-by-step video instructions, task tracking, and enables secure automatic collection of rating scales from parents or teachers. Supports both remote and in-clinic testing scenarios.
- QbMobile Smartphone-based application for clinical assessment of ADHD, enabling objective measurement of attention deficit hyperactivity disorder using mobile devices.
- QbAcademy Digital learning platform offering bite-size training videos and quizzes for both QbCheck and QbTest users, supporting self-paced onboarding and ongoing education for clinicians.
- QbAdmin Administration portal for QbTest (as distinguished from QbClinic which is used for QbCheck), providing test administration and report access for in-clinic testing.
Quantifiable outcome
- 44% reduction in time to diagnostic decision (AQUA study)
- +12 more outcomes
Companies that use Qbtech
Customer profileNamed customers8 records
Segments5 records
Ideal customer profiles5 records
Qbtech technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- Yes
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature8 records
Qbtech partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered regional and core.
- CHIRP (Child Health Integrated Response Pathway) - New ZealandregionalQbCheck integrated into the CHIRP clinical workflow in New Zealand, combining paediatrics, child development services and child and adolescent mental health services.
- ADHD Expert ConsortiumcoreCoalition of healthcare professionals including psychiatrists, psychologists, neurologists, developmental pediatricians, and patient advocates formed to advocate for improved ADHD care standards and evidence-based objective testing as standard of care.
- NHS Innovation Accelerator (NIA)coreQbTest selected as one of 11 innovations to join the NHS Innovation Accelerator, supporting spread of innovation across NHS England. This led to the Focus ADHD national programme.
- AHSN Network (Academic Health Science Network)corePartnership with AHSN Network for Focus ADHD national programme. Resulted in 70% of child clinics in England including QbTest. Awarded 'Best Mental Health Partnership with the NHS' in 2022 and 'Innovate Awards - Innovation Spread' in 2023.
- Gillberg FamilycoreThe Gillberg family joined forces with leading psychologist Fredrik Ulberstad to launch Qbtech in 2002, bringing clinical research expertise to the company's foundation.
Scale indicators15 records
Recent moves7 records
Expansion highlights6 records
Qbtech competitors and assessment
Company assessmentBroad incumbents
- Done: Direct-to-consumer virtual ADHD care provider offering diagnosis and stimulant prescribing online. Comparable to Qbtech as a customer/adjacent player: Done represents one of the high-growth virtual ADHD practices that Qbtech sells QbCheck into, and also competes for the same downstream virtual ADHD-assessment workflow.
- Akili Interactive: Digital therapeutic targeting ADHD and cognitive dysfunction (EndeavorRx), FDA-cleared and marketed through clinicians. Same ADHD customer segment and SaMD regulatory posture as Qbtech, but positioned in treatment rather than objective diagnosis.
- Cerebral: Large US telehealth platform offering ADHD evaluation and treatment among other mental-health conditions. Comparable to Qbtech as both a potential enterprise customer (for embedded objective testing) and a competitor in the virtual ADHD assessment workflow.
- Pearson Clinical Assessments: Established publisher of standardized psychometric and neuropsychological tests (e.g., Q-global platform) widely used for ADHD and learning-disorder assessment. Comparable to Qbtech as a competing objective-adjacent input into ADHD diagnosis, though distributed as traditional psychometric rather than motion-tracking SaMD.
Emerging players
- Altoida: Digital biomarker company using smartphone-based cognitive and motor tasks augmented with AR/AI for objective brain-function assessment (FDA Breakthrough Device for Alzheimer’s). Comparable to Qbtech in delivering device- and task-based objective brain assessment to clinicians, though focused on neurodegeneration.
- Myndlift: Provider of clinician-supervised home neurofeedback and attention-training programs marketed to ADHD patients and clinics. Comparable to Qbtech as a technology-mediated objective ADHD assessment/training option competing for the same clinician and patient mindshare.
- Neurotech International: Developer of Mente, an EEG-based home neurofeedback device for ADHD in children. Comparable to Qbtech in targeting the same clinician/patient ADHD population with an objective, technology-driven assessment, but using a different modality (EEG).
Direct peers
- Linus Health: Digital brain health platform offering tablet/PC-based cognitive assessments (e.g., DCTclock) used by clinicians for early detection and monitoring of cognitive impairment. Comparable to Qbtech in selling clinician-facing digital objective assessments that generate standardized reports.
- Creyos: Digital cognitive assessment platform providing clinician-administered, FDA-registered cognitive tests for attention, memory and executive function. Directly comparable to Qbtech because it sells SaaS-based objective cognitive/neuropsych testing to the same healthcare provider and research customer base.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Qbtech social profiles
Digital presenceQbtech compliance and trust
Trust signalCompliance7 records
Qbtech financial estimates
Financial estimateRevenue estimate
Valuation estimate
Qbtech leadership team
Management profileNumber of profiles
Profiles10 records
Qbtech subsidiaries and ownership
Company hierarchySubsidiaries3 records
Qbtech funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Qbtech M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Qbtech
What does Qbtech do?
Qbtech provides FDA-cleared, MDR-certified objective ADHD testing technology for healthcare providers. Its core offerings include QbTest, an in-clinic hardware-based assessment, and QbCheck, a web-based test usable remotely or in-clinic. Both products measure the three core ADHD symptoms (hyperactivity, impulsivity, inattention) using computerized attention-based tasks combined with motion tracking, comparing results to age- and sex-matched normative control groups.
Is Qbtech a public or private company?
Qbtech is a private company. It is classified as venture growth investor backed and is currently operating.
When was Qbtech founded?
Qbtech was founded in 2002. It employs 11 to 50 people.
Where is Qbtech based?
Qbtech is headquartered in Stockholm, Sweden, in the Europe region.
How does Qbtech make money?
Four revenue lines are on record. QbCheck Software Subscription (Growth Plan) is the primary driver. The others are qbCheck Enterprise Plans, qbTest Hardware and Subscription and professional Services and Training.
Who are Qbtech's main competitors?
Broad incumbents on record are Done, Akili Interactive, Cerebral and Pearson Clinical Assessments. Emerging players are Altoida, Myndlift and Neurotech International. Direct peers are Linus Health and Creyos.
Does Qbtech have an API?
Yes. API integrations are available as part of the Enterprise plan, enabling clinics to connect Qbtech's testing platform directly into their existing systems, sync reports into existing records, and standardize processes across teams. Specific API type, authentication method, rate limits, and versioning are not specified in the available source material. Developer documentation is at Not specified.
What industry is Qbtech in?
Qbtech's product category is ADHD Diagnostics Software. Its primary akta.pro industry code is HLAIADAO, Home Diagnostic & Self-Test OTC Kits, with a secondary code of HLAFAMAF, Toxicology & Therapeutic Drug Monitoring Laboratories. Its NAICS code is 621511 and its SIC code is 8071.